Notice2024-04432
Meeting of the Clinical Laboratory Improvement Advisory Committee
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 4, 2024
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting for the Clinical Laboratory Improvement Advisory Committee (CLIAC). This is a virtual meeting. It is open to the public, limited only by the number of webcast lines available. Time will be available for public comment, and the public is also welcome to submit written comments in advance of the meeting (see the public participation section below).
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 43 (Monday, March 4, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 43 (Monday, March 4, 2024)]
[Notices]
[Pages 15577-15578]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-04432]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Meeting of the Clinical Laboratory Improvement Advisory Committee
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting for the Clinical Laboratory Improvement Advisory
Committee (CLIAC). This is a virtual meeting. It is open to the public,
limited only by the number of webcast lines available. Time will be
available for public comment, and the public is also welcome to submit
written comments in advance of the meeting (see the public
participation section below).
DATES: The meeting will be held on April 10, 2024, from 10 a.m. to 6
p.m., EDT.
ADDRESSES: This is a virtual meeting. Meeting times are tentative and
subject to change. The confirmed meeting times, agenda items, and
meeting materials, including instructions for accessing the live
meeting broadcast, will be available on the CLIAC website at <a href="https://www.cdc.gov/cliac">https://www.cdc.gov/cliac</a>. Check the website on the day of the meeting for the
web conference link.
FOR FURTHER INFORMATION CONTACT: Heather Stang, M.S., Senior Advisor
for Clinical Laboratories, Division of Laboratory Systems, Center for
Laboratory Systems and Response, Office of Laboratory Science and
Safety, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, Mailstop V24-3, Atlanta, Georgia 30329-4027. Telephone: (404) 498-
2769; Email: <a href="/cdn-cgi/l/email-protection#266e75524748416645424508414950"><span class="__cf_email__" data-cfemail="450d1631242b22052621266b222a33">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Purpose: The Clinical Laboratory Improvement Advisory Committee
(CLIAC) is charged with providing scientific and technical advice and
guidance to the Secretary, Department of Health and Human Services; the
Assistant Secretary for Health; the Director, Centers for Disease
Control and Prevention (CDC); the Commissioner, Food and Drug
Administration (FDA); and the Administrator, Centers for Medicare &
Medicaid Services (CMS). The advice and guidance pertain to general
issues related to improvement in clinical laboratory quality and
laboratory medicine and specific questions related to possible revision
of the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
standards. Examples include providing guidance on studies designed to
improve quality, safety, effectiveness, efficiency, timeliness, equity,
and patient-centeredness of laboratory services; revisions to the
standards under which clinical laboratories are regulated; the impact
of proposed revisions to the standards on medical and laboratory
practice; and the modification of the standards and provision of non-
regulatory guidelines to accommodate technological advances, such as
new test methods, the electronic transmission of laboratory
information, and mechanisms to improve the integration of public health
and clinical laboratory practices.
Matters to be Considered: The agenda will include agency updates
from CDC, CMS, and FDA. Presentations and CLIAC discussions will focus
on the applicability of CLIA personnel requirements to preanalytic
testing, the role of artificial intelligence and machine learning in
the clinical laboratory, and the use of clinical standards to improve
laboratory quality. Agenda items are subject to change as priorities
dictate.
Public Participation
It is the policy of CLIAC to accept written public comments and
provide a brief period for oral public comments pertinent to agenda
items.
Oral Public Comment: Public comment periods for each agenda item
are scheduled immediately prior to the Committee discussion period for
that item. In general, each individual or group requesting to present
an oral comment will be limited to a total time of five minutes (unless
otherwise indicated). Speakers should email <a href="/cdn-cgi/l/email-protection#fcbfb0b5bdbfbc9f989fd29b938a"><span class="__cf_email__" data-cfemail="11525d585052517275723f767e67">[email protected]</span></a> or notify the
contact person above (see FOR FURTHER INFORMATION CONTACT) at least
five business days prior to the meeting date.
Written Public Comment: CLIAC accepts written comments until the
date of the meeting (unless otherwise stated). However, it is requested
that comments be submitted at least five business days prior to the
meeting date so that the
[[Page 15578]]
comments may be made available to the Committee for their consideration
and public distribution. Written comments should be submitted by email
to <a href="/cdn-cgi/l/email-protection#e5a6a9aca4a6a5868186cb828a93"><span class="__cf_email__" data-cfemail="96d5dadfd7d5d6f5f2f5b8f1f9e0">[email protected]</span></a> or to the contact person above. All written comments
will be included in the meeting minutes posted on the CLIAC website.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-04432 Filed 3-1-24; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 4, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.